The National Institutes of Health (NIH) announced that the preliminary data from Moderna’s Phase 3 COVID-19 vaccine trial demonstrates that the candidate (mRNA-1273) is safe and 94.5 percent effective. This analysis comes from an independent data and safety monitoring board (DSMB) overseeing the phase 3 trial.
The candidate was co-developed by Moderna and the National Institute of Allergy and Infectious Disease (NIAID), and utilizes Moderna’s mRNA delivery platform. The Phase 3 trial, which enrolled more than 30,000 participants at 100 clinical research sites, is also supported by Operation Warp Speed.
More detailed information about the trial can be found here.